Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
复制标题
根据世界卫生组织分类治疗转移性神经内分泌癌。
作者：
S. Artale;L. Giannetta;G. Cerea;D. Maggioni;P. Pedrazzoli;I. Schiavetto;M. Napolitano;S. Veronese;E. Bramerio;M. Gambacorta;A. Vanzulli;S. Pisconti;R. Pugliese;S. Siena
进行了一项单机构前瞻性试验，以评估生物治疗或化疗在转移性神经内分泌癌（NEC）中的疗效。治疗的选择是基于修订的WHO组织学分类标准，以确定这些癌症的标准化治疗方案。高分化NEC（WD-NEC; n=11）患者接受奥曲肽长效释放和干扰素-α-2b治疗最长1年;低分化NEC（PD-NEC; n=8）患者接受顺铂、L-亚叶酸和5-氟尿嘧啶联合化疗最长9个周期。5例患者（4例为WD-NEC）患有类癌综合征。在WD-NEC患者中（中位随访20个月，范围4-40），4例部分缓解，7例疾病稳定。在PD-NEC患者中（中位随访10.5个月，范围3-30），3例部分缓解，2例疾病稳定，3例疾病进展。WD-NECs和PD-NECs的2年生存率分别为88%和66%。3-4级副作用仅限于9%的血小板减少和12.5%的中性粒细胞减少。这两种治疗方案均具有良好的治疗指数，并且与先前报道的转移性WD-NEC和PD-NEC相比更有利。
A single institution prospective trial was conducted to evaluate the efficacy of biotherapy or chemotherapy in metastatic neuroendocrine carcinomas (NECs). The choice of therapy was based on the revised histological classification criteria of the WHO in an effort to define a standardized protocol for therapy of these cancers. Patients with well-differentiated NECs (WD-NECs; n=11) received therapy with octreotide long-acting release and interferon-alpha-2b for a maximum of 1 year; cases with poorly-differentiated NECs (PD-NECs; n=8) were given combination cisplatin, L-leucovorin and 5-fluorouracil chemotherapy for a maximum of 9 cycles. Five patients (4 with WD-NECs) had carcinoid syndrome. Among the patients with WD-NECs (median follow-up 20 months, range 4-40), 4 had partial responses and 7 had stable disease. In patients with PD-NECs (median follow-up 10.5 months, range 3-30), 3 had partial response, 2 stable disease, and the disease progressed in 3 cases. The 2-year survival rate in WD-NECs and PD-NECs was 88% and 66%, respectively. Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs.
影响因子：
158.5
作者：
MOERTEL, CG;LEFKOPOULO, M;KLAASSEN, D
通讯作者：
KLAASSEN, D
影响因子：
3.5
作者：
Trotti, A;Colevas, AD;Rubin, P
通讯作者：
Rubin, P